<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Kenai Therapeutics, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=45102></link><description><![CDATA[Kenai Therapeutics, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 03:42:00 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/03/12_1028147215_20240305093913_3107911744.png]]></url></image><language>ko-KR</language><item><title><![CDATA[Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases]]></title><link>https://www.newswire.co.kr/newsRead.php?no=985646</link><description><![CDATA[SAN DIEGO--(Business Wire/Korea Newswire)--Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, wi...]]></description><pubDate>Sun, 10 Mar 2024 13:55:00 +0900</pubDate></item><item><title><![CDATA[케나이 테라퓨틱스, 신경질환의 차세대 동종 세포치료제 개발 위한 8200만 달러 시리즈 A 파이낸싱 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=985647</link><description><![CDATA[샌디에이고--(Business Wire/뉴스와이어)--유도만능줄기세포(induced pluripotent stem cell, iPSC) 기술을 활용해 신경질환을 위한 동종 뉴런 대체 세포치료제(allogeneic neuron replacement cell therapies) 플랫폼을 발굴 및 개발하는 생명공학 기업 케나이 테라퓨틱스(Kenai Therapeutics)가 알래스카 퍼머넌트 펀드 코퍼레이션(Alaska Permanent Fund Corporation), 큐어 벤처스(Cure Ventures), 더 칼럼 그룹(...]]></description><pubDate>Sun, 10 Mar 2024 13:55:00 +0900</pubDate></item></channel></rss>